Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
IPO Year:
Exchange: NYSE
Website: zymeworks.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/21/2023 | $12.00 | Overweight | Wells Fargo |
1/4/2023 | $10.00 → $8.00 | Neutral | H.C. Wainwright |
12/20/2022 | $7.70 → $11.00 | Hold → Buy | Jefferies |
11/1/2022 | $40.00 → $8.00 | Buy → Neutral | H.C. Wainwright |
10/21/2022 | $8.00 | Outperform → Mkt Perform | SVB Leerink |
10/4/2022 | $45.00 → $9.00 | Overweight | Wells Fargo |
5/5/2022 | $14.00 | Neutral → Buy | Guggenheim |
3/15/2022 | $15.00 | Outperform | Evercore ISI |
2/9/2022 | $56.00 → $48.00 | Overweight | Wells Fargo |
12/10/2021 | $74.00 | Strong Buy → Outperform | Raymond James |
VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today reported, as required by the Nasdaq Stock Market Rule 5635(c) (the "Nasdaq Rule"), an equity inducement award to Ms. Leone Patterson, Zymeworks' Executive Vice President and Chief Business and Financial Officer. In accordance with the Nasdaq Rule, Zymeworks approved the grant of the following equity award to Ms. Patterson as a material inducement to Ms. Patterson entering into employment with Zymeworks: effective
VANCOUVER, British Columbia, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on September 4 at 8:45 am Eastern Time (ET) in Boston, MA.Morgan Stanley 22nd Annual Global Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on September 5
Veteran life sciences executive Mr. Neil Klompas to assume role of President and CEO Co-Founder and outgoing CEO Dr. Norma Biln to helm research and new product development and remain Chair of the Board of Directors Augurex Life Sciences Corp., a world leader in the early diagnosis of autoimmune diseases and a pioneer in the field of 14-3-3η based diagnostics, today announced the appointment of Mr. Neil Klompas as President and Chief Executive Officer. Mr. Klompas will succeed Augurex's Co-founder Dr. Norma Biln, who has served as President and CEO since the Company began operations in 2008. Dr. Biln will continue to be an integral part of the company transitioning into the interim r
VANCOUVER, British Columbia, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME) (the "Company"), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that its Board of Directors has authorized a Share Repurchase Program under which the Company may repurchase up to $60.0 million of the Company's outstanding common stock, par value $0.00001 per share. Zymeworks intends to commence the Share Repurchase Program with $30.0 million in initial repurchases anticipated to begin promptly and continue during the second half of 2024, demonstrating the C
Reported $395.9 million in cash resources as of June 30, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Priority Review of the Biologics License Application (BLA) granted for zanidatamab as second-line (2L) treatment for HER2-positive biliary tract cancers (BTC) in the United States with target action date of November 29, 2024The European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for zanidatamab in 2L BTCZanidatamab BLA acceptance in China triggering $8 million milestone payment under the terms of Zymeworks' Asia-Pacific license and collaboration agreement with BeiGeneOur partner
VANCOUVER, British Columbia, July 30, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences: BTIG Virtual Biotechnology Conference: Zymeworks' management will participate in virtual one-on-one meetings and a fireside chat on Tuesday, August 6 at 4:00 pm Eastern Time (ET).Wedbush PacGrow Healthcare Conference: Zymeworks' management will participate a panel discussion titled "ADCs and Old Lace: Antibody Drug Conjugates" ta
VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Leone Patterson as Executive Vice President, and Chief Business and Financial Officer, effective September 1, 2024. "After an extensive search, we are delighted to have Leone Patterson join us at this exciting time as we plan for our next stage of growth and development at Zymeworks," said Kenneth Galbraith, Chair and CEO of Zymeworks. "She brings more than 20 years of public company biotec
VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for ZW191, the Company's novel folate receptor-⍺ (FR⍺) targeted topoisomerase I inhibitor (TOPO1i) antibody-drug conjugate (ADC). "ZW191 is a differentiated product candidate in our pipeline that reflects the strength of our approach in developing best-in-class antibody-drug conjugates," said
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its second quarter 2024 financial results after market close on August 1, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on August 1, 2024 at 4:30 pm Eastern Time (ET). The event will be webcast live with dial-in details and webcast replays available on Zymeworks' website at http://ir.
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for ZW171, a novel 2+1 T-cell targeting bispecific antibody for mesothelin (MSLN)-expressing cancers. "We are excited to reach this R&D milestone with ZW171, reflecting our commitment to advancing innovative therapies for cancer treatment," said Paul Moore, Chief Scientific Officer of Zymeworks
8-K - Zymeworks Inc. (0001937653) (Filer)
8-K - Zymeworks Inc. (0001937653) (Filer)
424B5 - Zymeworks Inc. (0001937653) (Filer)
8-K - Zymeworks Inc. (0001937653) (Filer)
10-Q - Zymeworks Inc. (0001937653) (Filer)
8-K - Zymeworks Inc. (0001937653) (Filer)
8-K - Zymeworks Inc. (0001937653) (Filer)
144 - Zymeworks Inc. (0001937653) (Subject)
8-K - Zymeworks Inc. (0001937653) (Filer)
8-K - Zymeworks Inc. (0001937653) (Filer)
4 - Zymeworks Inc. (0001937653) (Issuer)
3 - Zymeworks Inc. (0001937653) (Issuer)
4 - Zymeworks Inc. (0001937653) (Issuer)
3 - Zymeworks Inc. (0001937653) (Issuer)
3 - Zymeworks Inc. (0001937653) (Issuer)
4 - Zymeworks BC Inc. (0001403752) (Issuer)
4 - Zymeworks Inc. (0001403752) (Issuer)
3 - Zymeworks Inc. (0001403752) (Issuer)
4 - Zymeworks Inc. (0001403752) (Issuer)
4 - Zymeworks Inc. (0001403752) (Issuer)
Wells Fargo resumed coverage of Zymeworks with a rating of Overweight and set a new price target of $12.00
H.C. Wainwright reiterated coverage of Zymeworks with a rating of Neutral and set a new price target of $8.00 from $10.00 previously
Jefferies upgraded Zymeworks from Hold to Buy and set a new price target of $11.00 from $7.70 previously
H.C. Wainwright downgraded Zymeworks from Buy to Neutral and set a new price target of $8.00 from $40.00 previously
SVB Leerink downgraded Zymeworks from Outperform to Mkt Perform and set a new price target of $8.00
Wells Fargo resumed coverage of Zymeworks with a rating of Overweight and set a new price target of $9.00 from $45.00 previously
Guggenheim upgraded Zymeworks from Neutral to Buy and set a new price target of $14.00
Evercore ISI initiated coverage of Zymeworks with a rating of Outperform and set a new price target of $15.00
Wells Fargo reiterated coverage of Zymeworks with a rating of Overweight and set a new price target of $48.00 from $56.00 previously
Raymond James downgraded Zymeworks from Strong Buy to Outperform and set a new price target of $74.00
ZW191 is the Company's novel folate receptor-⍺ (FR⍺) targeted topoisomerase I inhibitor (TOPO1i) antibody-drug conjugate (ADC). The Company expects to file applications seeking regulatory authorization to initiate clinical studies for ZW191 in non-US jurisdictions in the second half of 2024. ZW191 is the first of three ADC molecules incorporating the Company's proprietary ZD06519 payload designated for clinical development, with IND filings for ZW220 (NaPi2b ADC) and ZW251 (GPC3 ADC) on schedule for 2025.
BBY: 4% | UBS Upgrades Best Buy Co to Buy, Raises Price Target to $106 ZYME: 13% | Zymeworks shares are trading higher after the FDA cleared the company's Investigational New Drug application for Zw171 for mesothelin-expressing cancers, with the company expecting to initiate clinical development during 2024. QTTB: 9% | Q32 Bio shares are trading higher after Guggenheim initiated coverage with a Buy rating and a $100 price target.
Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China has accepted the BLA for zanidatamab for second-line treatment of HER2-positive BTC. Under the terms of Zymeworks' Asia Pacific license and collaboration agreement with BeiGene for the development and commercialization of zanidatamab, Zymeworks is entitled to receive an $8 million milestone payment. Zymeworks also remains eligible to receive up to $164 million based on
Throughout the last three months, 6 analysts have evaluated Zymeworks (NASDAQ:ZYME), offering a diverse set of opinions from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 2 3 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 1 0 0 2M Ago 1 1 0 0 0 3M Ago 0 1 1 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $12.0, a high estimate of $16.00, and a low estimate of $10.00.
HC Wainwright & Co. analyst Robert Burns reiterates Zymeworks (NASDAQ:ZYME) with a Neutral and maintains $10 price target.
Ratings for Zymeworks (NASDAQ:ZYME) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 2 2 0 0 Last 30D 0 0 1 0 0 1M Ago 1 1 0 0 0 2M Ago 0 1 1 0 0 3M Ago 0 0 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $12.4, a high estimate of $16.00, and a low estimate of $10.00. This current average has decreased by 2.75% fr
HC Wainwright & Co. analyst Robert Burns reiterates Zymeworks (NASDAQ:ZYME) with a Neutral and maintains $10 price target.
Citigroup analyst Yigal Nochomovitz maintains Zymeworks (NASDAQ:ZYME) with a Buy and lowers the price target from $17 to $16.
Reported $395.9 million in cash resources as of June 30, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Priority Review of the Biologics License Application (BLA) granted for zanidatamab as second-line (2L) treatment for HER2-positive biliary tract cancers (BTC) in the United States with target action date of November 29, 2024The European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for zanidatamab in 2L BTCZanidatamab BLA acceptance in China triggering $8 million milestone payment under the terms of Zymeworks' Asia-Pacific license and collaboration agreement with BeiGeneOur partner
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its second quarter 2024 financial results after market close on August 1, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on August 1, 2024 at 4:30 pm Eastern Time (ET). The event will be webcast live with dial-in details and webcast replays available on Zymeworks' website at http://ir.
Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Completion of rolling biologics license application (BLA) filing with the U.S. Food and Drug Administration (FDA) for zanidatamab as second-line treatment for biliary tract cancers (BTC) in the United States (U.S.) by our partner, Jazz PharmaceuticalsExpected initiation of a Phase 3 clinical trial for zanidatamab in the second half of 2024, for breast cancer patients who have progressed on trastuzumab deruxtecan (T-DXd), by our partner, Jazz Pharmaceuticals Two planned investigational new drug (IND) and foreign e
VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its first quarter 2024 financial results after market close on May 2, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 2, 2024 at 4:30 pm Eastern Time (ET). The event will be webcast live with dial-in details and webcast replays available on Zymeworks' website at http://ir.zymewo
Reported $456.3 million in cash resources as of December 31, 2023, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Initiation of rolling biologics license application (BLA) filing with the FDA for zanidatamab as second-line treatment for biliary tract cancers (BTC) in the United States (US) with anticipated completion of regulatory submission in 1H 2024 by our partner, Jazz PharmaceuticalsInitiation of Phase 3 confirmatory trial for zanidatamab as first-line treatment in BTC by our partner Jazz PharmaceuticalsExpected submission of BLA for zanidatamab with the National Medical Products Administration (NMPA) in China for tr
VANCOUVER, British Columbia, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its fourth quarter 2023 financial results after market close on March 6, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on March 6, 2024 at 4:30 pm Eastern Standard Time (EST). The event will be webcast live with dial-in details and webcast replays available on Zymeworks' website at ht
Net loss for the first nine months of 2023 decreased by 44% as compared to the same period in 2022Cash resources of $390.2 million as of September 30, 2023 expected to fund planned operations through at least the end of 2026, and potentially beyondUpdated clinical results from Phase 1b/2 study of zanidatamab plus chemotherapy and tislelizumab as first-line therapy for patients with advanced HER2-positive gastroesophageal adenocarcinoma (GEA) presented by our partner BeiGene at the European Society of Medical Oncology (ESMO) Annual CongressResults on quality of life outcomes from the Phase 2b HERIZON-BTC-01 study evaluating patients with zanidatamab-treated HER2-positive biliary tract cancer
VANCOUVER, British Columbia, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its third quarter 2023 financial results after market close on November 7, 2023. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on November 7, 2023 at 4:30 p.m. Eastern Time (ET). The event will be webcast live with dial-in details and webcast replays available on Zymeworks' website at http://ir.zymeworks.com/events-and-presentations. About Zymeworks Inc. Zymeworks Inc. (N
Net loss for the first six months of 2023 decreased by 45% as compared to the same period in 2022Cash resources of $431.4 million as of June 30, 2023 expected to fund planned operations through at least the end of 2026, and potentially beyondPresented full clinical results from Phase 2b study of zanidatamab monotherapy in previously treated HER2-amplified biliary tract cancers (BTC) at the Annual Meeting of American Society of Clinical Oncology (ASCO)Announces next investigational new drug application (IND) candidate, ZW220, a NaPi2b-targeted topoisomerase 1 inhibitor (TOPO1i) antibody drug conjugate (ADC), anticipated for IND filing in 1H-2025Additional preclinical and clinical data from mu
VANCOUVER, British Columbia, July 19, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its second quarter 2023 financial results after market close on August 10, 2023. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on August 10, 2023 at 4:30 p.m. Eastern Time (ET). The event will be webcast live with dial-in details and webcast replays available on Zymeworks' website at http://ir.zymeworks.com/events-and-presentations. About Zymeworks Inc. Zymeworks Inc. (NA
SC 13D - Zymeworks Inc. (0001937653) (Subject)
SC 13G/A - Zymeworks BC Inc. (0001403752) (Subject)
SC 13G/A - Zymeworks BC Inc. (0001403752) (Subject)
SC 13G - Zymeworks Inc. (0001403752) (Subject)
SC 13D/A - Zymeworks Inc. (0001403752) (Subject)
SC 13D/A - Zymeworks Inc. (0001403752) (Subject)
SC 13D/A - Zymeworks Inc. (0001403752) (Subject)
SC 13D - Zymeworks Inc. (0001403752) (Subject)
SC 13G/A - Zymeworks Inc. (0001403752) (Subject)
SC 13G/A - Zymeworks Inc. (0001403752) (Subject)
Veteran life sciences executive Mr. Neil Klompas to assume role of President and CEO Co-Founder and outgoing CEO Dr. Norma Biln to helm research and new product development and remain Chair of the Board of Directors Augurex Life Sciences Corp., a world leader in the early diagnosis of autoimmune diseases and a pioneer in the field of 14-3-3η based diagnostics, today announced the appointment of Mr. Neil Klompas as President and Chief Executive Officer. Mr. Klompas will succeed Augurex's Co-founder Dr. Norma Biln, who has served as President and CEO since the Company began operations in 2008. Dr. Biln will continue to be an integral part of the company transitioning into the interim r
VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Leone Patterson as Executive Vice President, and Chief Business and Financial Officer, effective September 1, 2024. "After an extensive search, we are delighted to have Leone Patterson join us at this exciting time as we plan for our next stage of growth and development at Zymeworks," said Kenneth Galbraith, Chair and CEO of Zymeworks. "She brings more than 20 years of public company biotec
VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Dr. Neil Gallagher to its board of directors effective April 2, 2024. "Dr. Gallagher is the sixth director to join our board of directors in the past twelve months as we continue to refresh and strengthen the Board governance and oversight required for the next stage of the Company's development and growth," said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. "His exp
VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Dr. Alessandra Cesano to its board of directors effective February 8, 2024. Dr. Cesano succeeds Dr. Kenneth Hillan, who will step down effective today after a successful 7-year tenure as a director of Zymeworks. "Zymeworks is honored to welcome Dr. Cesano to our board of directors," said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. "She brings more than 25 years of ex
VANCOUVER, British Columbia, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today announced that its board of directors will nominate Dr. Nancy Davidson for election to its board of directors at the Company's upcoming annual general meeting of stockholders to be held on December 7, 2023. "As the Company continues to execute on our strategy to support the approval and commercialization of zanidatamab while targeting five IND filings for new product candidates before the end of 2027, we are pleased to announce a significant proposed addition to our board of directors. With two prior
VANCOUVER, British Columbia, June 29, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the appointment of Mr. Carlos E. Campoy to its board of directors effective as of June 30, 2023. Mr. Campoy brings extensive strategic and financial leadership experience in the pharmaceutical and biotechnology sectors to the Zymeworks board of directors. He was also appointed as a member of the audit committee and the nominating and corporate governance committee of the board of directors. Mr. Campoy succeeds Dr. Natalie Sacks, who will step down effective as of June 30 after a successful 6-y
Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the appointment of Derek J. Miller to its board of directors effective April 10, 2023. Mr. Miller brings extensive commercial, corporate and business development, and senior leadership experience in oncology to the Zymeworks board of directors. "Derek brings over two decades of strategic, operational and commercial leadership and deep experience in oncology to the Zymeworks board," said Kenneth Galbraith, Chair and CEO of Zymeworks. "His guidance and expertise will be an important asset for us as we work with our collaboration partners, Jazz Pharmaceutica
Dr. Moore will lead Zymeworks' Early Research & Development Group responsible for advancing the Company's next-generation of multispecific antibody programs and antibody drug conjugate (ADC) programs into clinical studies Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that it is strengthening its senior leadership team with the appointment of Paul Moore, Ph.D., as Chief Scientific Officer, reporting directly to the Chief Executive Officer. Dr. Moore brings more than 25 years of US-based experience in biologics drug discovery and development in biotechnology research. His career efforts have
AVENTURA, Fla. and NATICK, Mass., June 7, 2022 /PRNewswire/ -- Cytovia Therapeutics, LLC ("Cytovia Therapeutics"), a global biotechnology company focused on empowering natural killer (NK) cells to fight cancer through multispecific antibodies and stem cell engineering, announced today that Luca Scavo, CPA, MBA has been appointed as Chief Financial Officer and James Priour, MBA has been appointed as Chief Product Officer, both effective immediately. "In the past year, Cytovia has graduated into a fully-integrated global biotech with R&D and cell manufacturing capabilities. As
Co-founder Dr. Ali Tehrani to remain as an advisor to the Company to assist in the transition expected to occur on or before February 1, 2022 Chief Financial Officer (CFO) Neil Klompas also promoted to the dual position of Chief Operating Officer (COO) and CFO effective immediately Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the appointment of Mr. Kenneth Galbraith as Chair and Chief Executive Officer (CEO) of Zymeworks, effective on or before February 1, 2022. Mr. Galbraith will succeed Zymeworks co-founder Ali Tehrani, Ph.D., who has served as President and CEO since 2003. Dr. Tehrani will remain a